التفاصيل البيبلوغرافية
| العنوان: |
On-Demand ICS + FABA Combinations in 6–11-Year-Old Children. |
| المؤلفون: |
Navarrete-Rodríguez, Elsy M., Del-Rio-Navarro, Blanca E., Larenas-Linnemann, Désirée, Castro-Rodriguez, Jose A. |
| المصدر: |
Journal of Clinical Medicine; Dec2023, Vol. 12 Issue 23, p7270, 16p |
| مصطلحات موضوعية: |
ASTHMATICS, ALBUTEROL, AGE groups, FORMOTEROL, BECLOMETHASONE dipropionate |
| مستخلص: |
In recent years, some new concepts have been added to asthma treatment such as "anti-inflammatory reliever" (β2-agonist use associated to an inhaled corticosteroid (ICS) as a reliever treatment) that combines the benefits of both therapies and provides short- and long-term benefits for treatment in asthma patients. Robust evidence has been presented in patients over 12 years, and the main changes in the international guidelines for asthma treatment were originally made in this age group. However, a few suggestions have been added to treatments in younger patients, in part because of the scarce evidence that exists in this group. We aim to analyze the information regarding the utilization of ICS + fast-acting beta-agonist (FABA) combination in children between 6 and 11 years. Although up until today only three published trials exist (two studies use beclomethasone + albuterol and one study uses budesonide + formoterol), they provide significant information on the benefits of ICS + FABA use in this population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder